
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14D-9
(Rule 14d-101)

**SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934**

G1 THERAPEUTICS, INC.
(Name of Subject Company)

G1 THERAPEUTICS, INC.
(Name of Persons Filing Statement)

COMMON STOCK PAR VALUE \$0.0001 PER SHARE
(Title of Class of Securities)

3621LQ109
(CUSIP Number of Class of Securities)

Monica Roberts Thomas, Esq.
Chief Legal and People Officer
700 Park Offices Drive, Suite 200
Research Triangle Park, NC 27709

With copies to:

Matthew J. Gardella, Esq.
Jason S. McCaffrey, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, MA 02111
(617) 542-6000

Sarah Young, Esq.
Ropes and Gray LLP
Prudential Tower
800 Boylston Street
Boston, MA 02199
(617) 951-7000

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of the persons filing statement)

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

The information set forth under Items 1.01, 5.02 and 9.01 of the Current Report on Form 8-K filed by G1 Therapeutics, Inc. on August 7, 2024 (including all exhibits attached hereto) is incorporated herein by reference.
